Thymosin beta-4

What it is

Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid peptide that is among the most abundant proteins in human cells. The synthetic fragment commonly sold as “TB-500” corresponds to the active region (residues 17–23) and is sometimes formulated as a longer subset of the full Tβ4 sequence.

Thymosin beta-4 was first identified in calf thymus tissue in 1981 by Allan Goldstein and colleagues and was initially thought to be a thymic immune-modulating peptide (which is why “thymosin” is in the name). Subsequent research described broader biological roles, particularly in cell migration, tissue repair, and angiogenesis. Tβ4 has been studied in human clinical trials for cardiac repair, dry eye disease (FDA fast-track designation), and chronic wound healing.

“TB-500” typically refers to the active fragment, although the name is also applied to the full-length molecule. In equine sports medicine, Tβ4 (often as TB-500) has been used for soft-tissue injury and is on most racing organizations’ prohibited substance lists. Thymosin beta-4 and TB-500 are not FDA-approved for any use in the United States.

Mechanism of action

Proposed mechanisms come from laboratory and animal research. Tβ4’s primary known biological function is regulation of actin polymerization. It binds G-actin (monomeric actin) and prevents its polymerization into F-actin, acting as a sequestering protein in the actin dynamics involved in cell migration, shape change, and division. Effects attributed to Tβ4 in research include:

• Cell migration: in laboratory and animal studies, Tβ4 has been reported to increase endothelial cell, stem cell, and progenitor cell migration toward sites of injury.
• Angiogenesis: has been reported to increase VEGF expression and new blood vessel formation in animal models of tissue injury.
• Inflammatory signaling: in experimental models, has been reported to reduce pro-inflammatory cytokine production.
• Stem cell recruitment: in animal studies, has been associated with mobilization of bone marrow-derived progenitor cells to injury sites, a hypothesized mechanism for effects seen in cardiac models.
• Anti-apoptotic effects: in animal models of ischemic injury (e.g., stroke or myocardial infarction), has been reported to reduce programmed cell death in surrounding tissue.

The fragment has a molecular size of approximately 5 kDa; the full-length peptide is approximately 5.4 kDa.

Research findings

Preclinical work: there is an extensive animal literature across tissue types. In rodent cardiac infarction models, Tβ4 administration was associated with improved ventricular function and reduced scar size. Improvements were also reported in animal models of corneal injury, dermal wound healing, and CNS injury.

Human cardiac trials: a Phase II trial (TIME-1) explored Tβ4 in patients after myocardial infarction. The development program did not proceed to approval.

Dry eye disease: RegeneRx pursued FDA approval for a Tβ4 eye drop (RGN-259) for severe dry eye and neurotrophic keratopathy. Phase II and III trials have been published; benefit in people has not been established. The FDA granted Fast Track designation, but the product has not been approved.

Chronic wound healing: small Phase II trials in venous stasis ulcers and pressure ulcers have been published; benefit in people has not been established.

Well-controlled human trials establishing the effectiveness and safety of TB-500 for any use are lacking.

Side effects and contraindications

Human safety of TB-500 has not been established in well-controlled trials, and long-term effects are unknown. Products sold outside regulated channels (e.g., “research peptides”) may vary in purity, dose, and sterility.

Theoretical concerns:

• Malignancy: the angiogenic and cell migration-promoting effects reported in research raise theoretical concerns about supporting tumor growth or metastasis, particularly in people with active or recent cancer or undiagnosed lumps.
• Pregnancy and breastfeeding: avoided in absence of safety data.

What we don’t yet know

Despite the size of the preclinical literature and several human trials, no human RCT has established TB-500 as a treatment for any specific injury type. The relative properties of the TB-500 fragment vs. full-length Thymosin beta-4 have not been characterized in people. Long-term human safety is not known. The relative contribution of each proposed mechanism (cell migration, angiogenesis, anti-apoptotic effects) to the outcomes seen in animal studies remains an open question. TB-500 remains an investigational compound with preclinical evidence but without established clinical validation.